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6Abstract
In genetic epidemiology, population-based disease registries are commonly used to
collect genotype or other risk factor information concerning affected subjects and
their relatives. This work presents two new approaches for the statistical inference of
ascertained data: a conditional and full likelihood approaches for the disease with
variable age at onset phenotype using familial data obtained from population-based
registry  of  incident  cases.  The  aim  is  to  obtain  statistically  reliable  estimates  of  the
general population parameters. The statistical analysis of familial data with variable
age at onset becomes more complicated when some of the study subjects are non-
susceptible, that is to say these subjects never get the disease. A statistical model for a
variable age at onset with long-term survivors is proposed for studies of familial
aggregation, using latent variable approach, as well as for prospective studies of
genetic association studies with candidate genes. In addition, we explore the
possibility of a genetic explanation of the observed increase in the incidence of Type
1 diabetes (T1D) in Finland in recent decades and the hypothesis of non-Mendelian
transmission of T1D associated genes. Both classical and Bayesian statistical
inference were used in the modelling and estimation. Despite the fact that this work
contains five studies with different statistical models, they all concern data obtained
from nationwide registries of T1D and genetics of T1D. In the analyses of T1D data,
non-Mendelian transmission of T1D susceptibility alleles was not observed. In
addition, non-Mendelian transmission of T1D susceptibility genes did not make a
plausible explanation for the increase in T1D incidence in Finland. Instead, the
Human Leucocyte Antigen associations with T1D were confirmed in the population-
based  analysis,  which  combines  T1D  registry  information,  reference  sample  of
healthy subjects and birth cohort information of the Finnish population. Finally, a
substantial familial variation in the susceptibility of T1D nephropathy was observed.
The presented studies show the benefits of sophisticated statistical modelling to
explore risk factors for complex diseases.
71. Introduction
All the five papers presented in this thesis introduce new ideas of statistical inference in
genetic-epidemiological family studies of complex diseases with variable age at onset. In
papers I-III classical statistical inference is applied and in papers IV-V Bayesian inference is
preferred to obtain estimates of the model parameters and their variation. A common theme in
papers I-IV is the estimation of population parameters of interest when the observed familial
data have been selected – ascertained – from a population-based disease registry of incident
cases of T1D. Phenotype-based selection of families, ascertainment, is a common way of
collecting data in genetic studies of rare human diseases. Although different statistical models
are used in each of the five papers: multinomial model (paper I), Poisson model (paper II),
fixed effect long-term survivor model (paper III), discrete time hazard model (paper IV) and
random effects long-term survivor model (paper V) all of these models are applied to the
genetics of T1D or Diabetic Nephropathy.
All  the  data  used  in  the  analysis  comes  from two nationwide  population-based  registries  of
T1D in Finland. None of the currently available statistical methods for genetic analyses of
variable age at onset phenotype is directly applicable to the problems of population-based
family data: how to model the variable age at onset phenotype (trait) and account for
population-based ascertainment of variable age at onset disease in the statistical analysis.
Statistical analyses of non-randomly collected family data in genetics dates back to the
founders of the classical statistical inference (1) and has gained increasing interest in recent
years, because of the rapid improvement in computational capabilities needed by complex
statistical models (2,3).
Survival analysis of times to event of interest has been utilized many decades in
epidemiological studies and has been applied increasingly to the genetic studies of complex
diseases with variable age at onset (4). Many common complex diseases, such as coronary
heart disease and different forms of diabetes, share two important characteristics: disease can
be  diagnosed  at  any  age  and  not  all  subjects  become  affected  during  their  lifespan.  It  thus
seems natural to assume that subjects can be classified into those who are susceptible to the
8disease and those who are not – called non-susceptible (5). In papers III and V the framework
of long-term survivors (6) is modified for genetic studies of familial aggregation and
association.
Problems of statistical inference in all of the five papers in this dissertation originated from
the familial data collected in studies of the genetics of T1D or its complications. The detailed
pathogenesis  of  T1D  remains  unsolved,  although  the  primary  role  of  Human  Leucocyte
Antigen region (HLA), located in chromosome 6q, in T1D risk has been well established
since the early 1970’s (7) and later confirmed by genome-wide studies (8,9). Yet there are
still many unresolved issues related to the more detailed characterization of the gene(s) in the
HLA region (10). In this work, articles I, III and IV concern hypothesis of the genetic
influence  of  HLA-A,  HLA-B  and  HLA-DRB1  loci  on  T1D  risk.  Paper  II  is  not  directly
related to HLA but explores possible genetic effects to explain the observed increasing trend
in the incidence of T1D in Finland, assuming a causal variant with effects identical to those
observed  for  the  HLA-DR3,4  genotype.  In  paper  IV,  familial  aggregation  of  the  partially
latent susceptibility and age at onset of nephropathy among Type 1 diabetics is modelled and
estimated.
The aims of this dissertation were to develop statistical methods to analyze registry-based
data and on the other hand characterize genetic effects of HLA A, B and DR loci both to age
at onset and to susceptibility of T1D. Next, an overview of the statistical techniques in genetic
epidemiology with focus on variable age at onset phenotype, ascertainment and genetic
association is presented. A short introduction to the epidemiology and especially genetic
epidemiology of T1D is given next. The study designs and data collection in the DiMe and
the DERI studies are then described. The proposed statistical models and inference are
described and results concerning T1D are presented, with discussion of the models and results
at the end of the thesis.
92. Genetic epidemiology
Genetic  epidemiology  may  be  viewed  as  the  study  of  the  joint  action  of  genes  and
environmental factors in causing disease in human populations and their patterns of
inheritance  in  families  (11).  It  is  then  evident  that  genetic  epidemiology  focuses  on  the
familial, especially genetic, determinants of disease. The process of establishing genetic basis
of a phenotype in genetic epidemiology, depending on the questions asked and data at hand,
can be classified  as follows (articles in this thesis are given by Roman numerals):
 Analysis of familial aggregation: Does the potentially genetically determined
phenotype aggregate in families? (paper V)
 Segregation analysis: Find a genetic model that adequately explains patterns of
phenotypes in families (paper V)
 Linkage analysis: Determine the approximate chromosomal location of disease
gene(s) using information on the known locations (markers) in the chromosome(s)
 Association analysis: Localize the gene in more detail, look for association with
candidate genes, characterise possible causal genes (papers I-IV)
 Gene effects – gene expression, microarrays etc. Does the polymorphism affect
mRNA?
2.1 Summary of the basics of Human Genetics
Human DNA is organized in 46   chromosomes – 22 homologous pairs and two sex-specific
chromosomes (called X and Y). Each chromosomal strand is made of sequence of nucleotide
bases of four types: adenine (A), cytosine (C), guanine (G) and thymine (T), which are bound
by covalent bonds. Double-stranded DNA is replicated by breaking the two strands and then
constructing a new complementary strand for each. A single strand of DNA may also act as a
template for a complementary strand of RNA.  In this transcription RNA is identical to DNA,
but T is replaced by U (Uracil). Genes are regions of DNA from which the transcribed DNA
encodes to tell the cell how to construct aminoacids to make proteins. Genes contain regions
of variable length called exons and introns. Mature RNA is processed by cutting out introns.
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In translation, the splices the exonic sequencies produce mRNA, which codes for proteins.
The ability of genes to alterate protein function is the basis of genetic influence on
phenotype(s).
According to Mendel’s first law, each parent donates one of each pair of the chromosomal
strand with equal probability.  At a given locus, many different forms of gene representing
individual mutations may exist, called alleles. Alleles are differentiated by the repeats of
nucleotide bases. An unordered pair of alleles at the same locus is called a genotype.
Genotype can be treated as unobserved variable in the statistical analysis. When the parental
source of alleles is known genotype can be called ordered genotype.  A combination of alleles
at multiple loci along same chromosomal strand is known as haplotype. A heterozygous
individual carries two different alleles, while an homozygous individual has two copies of the
same allele. Observable, already known locations in the chromosomal strands are called
markers, and two types of markers are currently widely used in genetic epidemiological
studies: microsatellite and single nucleotide polymorphism markers (SNPs). Markers can be
highly polymorphic, that is genes usually have many possible alleles or markers that contain
only some simple aminoacid sequences. Some regions in human genome, like HLA region in
chromosome 6, are highly polymorphic.  Markers at the HLA region have until recently been
typed with serological methods, based on the antibody production, rather than modern PCA-
based genotyping or more recent high throughput methods (9).
Our ability to locate disease genes in linkage and association studies in humans is based on
the cross-over (meiotic recombination) events during meiosis. Meiosis is a special case of cell
division where sperm and egg cells are created. In meiosis the DNA material can be changed
in a cross-over event when DNA from one parental strand switches to another parental strand.
There are several phases in meiosis as described in Figure 1, where cross-over occurs in
Prophase 1. There homologous chromatids pair up and form physical connections
(chiasmata). DNA strands break up and swap material from one chromosome to material from
another. This results gametes having material from both homologues of a chromosomal pair.
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Figure 1. Phases of meiosis (www.accessexcellence.org/AB/GG/meiosis.html)
In Figure 2, a cross-over event has occurred somewhere between A and B loci. During
prophase I the four available chromatids are in tight formation with one another. While in this
formation, homologous sites on two chromatids can mesh with one another, and may
exchange genetic information. In Figure 2, a part of the maternal chromatid containing A7,
are joined with paternal chromatid containing B2 to form a recombinant chromatid and
similarly another recombinant chromatid containing  A5 and B3 is formed.
12
A1 A5A7 A9 A1
A7 A5
A9
A1
A7 A5
A9
B1 B2 B3 B4 B1
B1
B2 B3
B4
B2
B3 B4
Paternal
chromatids
Maternal
chromatids
A7 A5
Figure 2. Crossing-over event, producing two recombinant and two non-recombinant
chromatids.
The frequency of recombination between two locations depends on their distance, because
recombination can occur with small probability at any location along chromosome. Under the
assumption that crossover event occur randomly the expected number of crossover events can
be modeled using the Poisson model, resulting a Haldane’s map function. This is the most
simply function that relates recombination fractions to map distances. Genetic Linkage
analysis relies on the fact that if a marker is passed down through a family consistently with
the disease then it can be said that gene with a functional effect is located close to that marker.
Linkage analysis has been less successful to locate genes influencing complex diseases than
monogenic diseases, mainly due to lower statistical power (12). Therefore, genetic association
studies have been used to dissect genetics of complex diseases and later in this thesis
principles of genetic association are described.
2.1.1 Human Leucocyte Antigen
The Major Histocompatibility Complex (MHC) is a large gene-dense region in the genome of
most mammalians. It plays an important role in the immune system and reproduction
vertebrates. In humans MHC is known as the Human Leukocyte Antigen system (HLA). HLA
consists of series of closely linked and highly polymorphic genes, spanning about 4 Mb on the
short arm of the chromosome (6p21.1-6p21.3). HLA genes can be classified into three major
subgroups: class I, class II and class III. This grouping is based on the encoding functions and
13
expression of the molecules (13). HLA-A and HLA-B loci belong to class I and HLA-DR to
class II. Locations of the HLA-A, HLA-B and HLA-DR loci, studied in the papers I, III and
IV, are shown in Figure 3.
Figure 3. Locations of HLA-A, HLA-B and HLA-DR loci on chromosome 6.
At the moment, all the known loci at the HLA have currently nearly 3,000 alleles that have
been detected in the human population (http://www.ebi.ac.uk/imgt/hla/stats.html, last updated
October 2007), of these the most variable are HLA-B and HLA-DR(B1). Known variant
alleles according to the international ImmunoGenetics –project (IMGT-HLA) database for
loci studied in here are HLA-A 617, HLA-B 960 and HLA-DRB1 626. The first complete
DNA sequence and gene map of HLA was published in 1999, and estimated 224 genes in the
region (14). To keep track on the alleles of various loci at the HLA region, there is a
nomenclature concerning HLA and it is evaluated at every two years. Two systems of the
nomenclature can be applied to the naming of HLA alleles:
1) The older system is based on serological (antibody-based) recognition. In this system
antigens were assigned letters and numbers (e.g. HLA-DR4 or, shortened, DR).
Because  all  the  HLA  genotype  data  of  the  Childhood  Diabetes  in  Finland  study
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(DiMe) in this dissertation is obtained with serological methods we use this notation
of the HLA-A, HLA-B and HLA-DR alleles.
2) The “newer” system is based on the nucleotide sequencing based recognition of the
alleles and thus allows for more refined definition of alleles. A "HLA" is used in
conjunction with a letter * and four or more digit number (e.g. HLA-B*0801,
A*68011, A*240201N N=Null) in order to designate a specific allele at a given HLA
locus.
The MHC genes and the cell surface protein molecules encoded by the MHC play a critical
role in T-cell recognition and thus in human immune system. The HLA system, by virtue of
its extreme polymorphism, ensures that few individuals are identical and thus the population
at large is well equipped to deal with attack. Because some HLA antigens are recognised on
all of the tissues of the body (rather than just blood cells), the identification of HLA antigens
is  described  as  "Tissue  Typing".   Routine  tissue  typing  identifies  the  alleles  at  three  HLA
Class  I  loci  (HLA-A,  HLA-B,  HLA-C)  and  three  Class  II  loci  (HLA-DR,  HLA-DP)  and  is
based on the structure of the antigens produced and their function. Class I genes encode
glycoproteins  expressed  on  the  surface  of  almost  all  nucleated  cells  of  the  body and  class  I
molecules are encoded by the A, B and C region in humans. Class II genes encode
glycoproteins expressed primarily on antigen-presenting cells (macrophages, dendritic cells,
B cells) where they present the processed antigen to the T helper cells. These molecules are
encoded by the class II  region. HLA Class I  genes and the HLA Class II  genes each spread
over approximately one third of the length of HLA region. The remaining section sometimes
called class III, contains loci responsible for complement, hormones, intracellular peptide
processing and other developmental characteristics, including tumour necrosis factor (TNF).
These loci are not actually a part of the HLA complex, but since they are located within the
HLA region are included in the nomenclature, because its components are either related to the
functions of HLA antigens or are under similar control mechanisms to the HLA genes. The
HLA region has been shown to link and/or associate to many diseases, including T1D (9).
2.2 Fundamental concepts in genetic epidemiology
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The first step in studies of genetic epidemiology uses descriptive methods to document
familial aggregation for trait that cannot be explained solely by environmental factors. In the
next step, heritability is studied. When the phenotype is continuous, heritability means the
proportion of variation in trait due to genetic factors. Variance component or path models are
commonly used statistical methods in heritability studies. When the phenotype is
dichotomous (e.g. healthy, affected) there is a threshold in the latent liability (continuous)
describing the cutoff point which divides subjects into the two groups. Segregation analysis
tests models of inheritance on family data and does not require observed genetic markers,
which are polymorphic genes whose physical locations are known. Any possible phenotype
can be analysed in segregation analysis e.g. dichotomous, continuous or censored continuous.
Modern genetic association studies use information on the historical recombinant events that
could cause linkage disequilibrium, and there are sophisticated statistical methods for the
analyses of genetic data to localise and characterize in more detail gene responsible of
variation in phenotype. Genetic association studies have become more popular when dense
marker maps have become available using microsatellite markers or SNP’s.
Segregation analysis compares patterns of trait in families to some pre-specified inheritance
model. In order to relate genes or markers to the phenotype, we need a mathematical function
describing the relationship. This function is called penetrance and it gives a probabilistic
model that relates genotypes to phenotype using a conditional probability function:
P(phenotype | gene(s) and/or environmental factors). In all of the studies presented here,
phenotype is a variable age at onset phenotype. The simplest directly observably phenotype is
binary (affected/healthy), but it can be continuous (cholesterol, blood pressure). This
dissertation focuses on phenotype with variable age at onset, because T1D can be diagnosed
at any age in contrast to phenotypes expressed immediately at birth.
2.3 Statistical inference in genetic epidemiology
Statistical inference is based on assuming a probabilistic model which could have produced
the data. Because both classical (frequentist) and Bayesian statistical inference is used in this
thesis, a short overview of both is given. The classical inference is based on the mathematical
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probability density function of the data  Y,...,YY n1 given the unknown but fixed model
parameters :  |Yf .  If the observations can be assumed to be independent and identically
distributed (i.i.d.), the likelihood function of the observations is simply a product of the
density functions of each observation, i.e.    


n
i
i |Yf|Yf
1
. Maximum likelihood
estimator is the value of , which maximizes the above likelihood function. The classical
statistical inference relies on the assumption that the mechanism which generated the data
remains unchanged, and the data generation process can be repeated. This classical
framework has been applied to the data analysis in papers I-III. Note that in the context of
classical inference the density function describes the generation of the data. In the genetic
epidemiology observations are rarely independent because commonly we observed data from
relatives (pedigrees). In order to analyze data of dependent observations one can use
multivariate distributions or introduce unobserved latent random variables. Familial
dependency in the age at onset and susceptibility were accounted for using latent variable
approach in paper IV in this thesis.
The research questions in papers IV and V were modelled using Bayesian inference. The core
of the Bayesian inference is the joint probability density of the observed data Y and , which
is treated as random variable in the analysis unless value is known. The statistical inference is
based on the posterior distribution of
    
   
     ,|YfYf
|Yf
Yf
YfY|f  gg,
where  Yf  is  the  marginal  probability  density  function  of  the  data  obtained  either  by
summing over     g|Yf  if  is discrete or integrating if  is continuous,  |Yf  is the
likelihood function and  g  is the prior density function which incorporates researchers
beliefs (in probability formulation). If the value of  is unknown it needs to be defined. This is
done by the researcher by defining a prior distribution of . We end up with a posterior
density, which in fact is the prior multiplied by the likelihood. If the prior is vague, inference
is dominated by the data and similarities with classical approach can occur. Bayesian methods
provide natural tools to deal with missing/latent data by sampling from the posterior
distribution of missing data than the classical approach. Because the posterior distribution
rarely can be solved analytically, developments in numerical methods and computer capacity
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have made possible to apply Bayesian modelling increasingly also to genetic epidemiology
(15). Computationally intensive methods are needed to obtain samples of the posterior
density. One of the oldest methods is Metropolis-Hastings algorithm (16), which was used in
paper IV to obtain samples from the joint posterior of missing susceptibility status and the
model parameters. In paper V several sampling algorithms were used, all implemented in the
OpenBugs program (17).
2.4 Phenotype with variable age at onset
In the survival analysis a non-negative random variable *iT  is modelled.  This is the ‘true’
time of the event of interest of subject i, e.g. ‘true’ age at onset of disease. Censoring refers to
a case where we observe the true time *iT only if it does not exceed subject i’s censoring time
Ui, otherwise we observe Ui (right censoring). Type I censoring is assumed and it occurs
when subjects are put on a test at time 0 and are followed for a fixed period of time. Then we
observe failure times of those subjects that failed and while for the rest we know that they did
not fail before and are said to be censored. Observed data of variable age at onset disease data
consists of pairs of survival times and censoring indicators    nn ,T,,,T 		 11 , where
 i*ii ,UTT min  and 1	i  if  subject i failed during the follow-up and 0 if censored.
A phenotype with variable age at onset can be characterized by the distribution function
   
 ;tTp;tF i*ii , survival function       ;tTp;tF;tS i*iii 1  and density
function    
i
i
i dT
;tdF;tf  .  Hazard function     


;tS
;tf;t
i
i
i , expresses limiting
probability that the event of interest occurs in a given time interval, conditionally on that the
event of interest has not occurred before the beginning of the interval and divided by the
width of the interval. Survival models provide natural means to deal with censoring - an
important feature of age at onset phenotype. Assuming independence of the observations, the
likelihood function can then be written        



n
ii
ii TFTfcTL
1i
1
;1;;
		
 , where c
is a constant and c is not a function of the model parameters. Survival models can be written
using the distribution function or the hazard function. One choice is the Weibull distribution
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with a shape parameter  and scale parameter  having density
  
























ii
i
TT
,;Tf exp
1
 (paper V) or the Gamma density function with shape
parameter (a) and scale parameter (s)
 







 
s
TT
as
a,sTf iaiai exp
1);( 1   (paper III), where
() is the gamma-function. Measured covariates zi can be modelled using the Weibull model
by defining the log of the scale parameter of subject ii to be a function of the covariates and
regression coefficients: log(i)= iz'0   , where  is a (p1) vector of regression coefficients
and  ipii z,...,zz 1  is vector of the observed covariates values.
Survival models have long history in epidemiology, and the variable age at onset has been
analysed using survival models developed for genetic-epidemiological studies during past few
decades. Proportional hazards models have been applied to both the segregation and linkage
(4). This semi-parametric survival model can be written using the hazard function i(t) = 0
(t)exp(’zi). In this model formulation covariate information (observed genetic markers) is
related to the hazard of disease age at onset through exponential function that multiplies the
baseline hazard function. In order to include familial correlation into event time models a
frailty model have been introduced by Vaupel et al. (18). It was later developed for genetic
studies (19-21). Frailty is a latent random effect variable that can be added into the
exponential part of the previous hazard model. In genetic epidemiology a shared frailty model
indicates that all members of the same family will have the same frailty. A discrete time
formulation of the survival model, in which the time scale is divided into small time periods
with constant baseline hazard (piecewise constant hazard model) is applied in paper IV of this
work.  In the analysis of event data likelihood can be based on the Poisson density.  In paper
II we make a use of the Poisson probability density  
!d
e;df
d


, where  is the
parameter (mean number of events) and d is the observed number of events. This model is
useful when the disease is rare, like T1D is.
Survival models described above can be extended to incorporate an idea that not all subjects
will develop outcome even if followed forever. The long-term survivor model elegantly
combines binary susceptibility phenotype and survival phenotype (6). It is assumed that
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censoring distribution is proper, e.g.     1

TGlimG
T
, and that the cumulative
distribution function     pTFlimF
T


 is strictly less than one. Then the case p<1
corresponds to the presence of non-susceptibles in the population. In order to allow true
survival times t* to be infinite and to introduce a proper c.d.f. to describe lifetimes of non-
susceptible subjects, a latent Bernoulli random variable Di for each subject i, which is one
(susceptible) with probability p and 0 (non-susceptible) with probability 1-p is introduced.
Because we do not know who is non-susceptible, of  all subjects, Di is a partially latent
random variable. The c.d.f. for true survival times is  then
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which essentially rescales the possibly improper F to a new distribution F0 with total mass 1.
The likelihood function for the observed survival times with non-susceptibles can then be
written as
       



n
ii
ii TFpTfcTL
1i
1
0 ;1;;
		  .  This likelihood was applied in paper III,
when ascertainment was taken into account. Maller et al. (6) worked on the problems of  right
extremes, sufficient follow-up and testing of the presence of immunes and provided many
statistical properties of the LTS model. In the Bayesian formulation of this model (22),
susceptibility status Di is treated as partially latent variable and sampled as a part of the joint
posterior distribution as it has been done in the paper V. There are also some very recent non-
Bayesian applications of this model in the genetic studies (23,24).
2.5 Ascertainment
Phenotype-based collection of families, ascertainment, is a common type of data collection
for rare diseases in genetic epidemiology. This leads to families in which affected individuals
are over-represented compared to the population as a whole, and thus possibly falsely
increasing the statistical power when estimating genetic parameters such as recurrence risk
ratios (25).When the aim of the study is to make inference of the model parameters in the
general population from which the observed data has been ascertained, it must also be
remembered that statistical inference has to take into account the process of data collection. In
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naive statistical analysis ignoring ascertainment process, the statistical inference of the model
parameter estimates are biased – this is called ascertainment bias. Crucial for the proper
statistical analysis of such data is that the ascertainment process should be well documented
and clearly defined. Problems related to ascertainment have been studied extensively from the
early days of modern statistics (1). In the classical ascertainment model a binary phenotype
(healthy, affected) is assumed and a person is affected with a constant probability 
independently of others. An affected subject becomes a proband with constant probability  .
In other words, a single individual causes a family to enter the sample (proband)
independently of all other persons in a particular sibship.  If we observe all sibships with at
least one affected ( =1, complete ascertainment), we can compute the conditional probability
of observing R=r affected subjects given the size of sibship S=s and at least one affected
    
 
 s
rsr
r
s
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1
1
1 . The likelihood function is
the product of the previous probabilities over the possible sizes of sibships and the numbers of
affected subjects.
The past studies of ascertainment focused either on the definition of discrete sampling units or
on construction of more complex conditional likelihood functions based on the above
definition of the proband (26-29). The problem of ascertainment can be handled by choosing
the appropriate study design: a case-parent triad design in which the formulation of the
conditional likelihood is based on the probability of the genotype of the case conditional on
the case status and the possible parental genotypes (30). This transmission/disequilibrium test
(TDT) based on conditional likelihood avoids ascertainment bias by conditioning on the
parental origin and its different modifications have gained much attention as a way to avoid
population stratification (28). However, one cannot estimate the absolute risk, because data
are restricted to cases only and information concerning the population is not available.
Development of computationally intensive methods has produced novel statistical methods
for the problems of complex ascertainment (2). Recently, Burton (3) explored the possibility
of heterogeneity in the risk of disease in the general population. This expands the classical
framework of ascertainment where a fixed probability of disease was assumed. Analysis of
family data through probands with variable age at onset in disease registry data has not been
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studied much. In their article Langholz et al. (31) concluded that in the estimation of rate
ratios in addition to the rare disease assumption, it is also essential that the covariate
distribution does not depend on calendar time or birth order (exchangeability assumption). In
paper I of this dissertation, we construct a likelihood function conditional on the
ascertainment by considering all sibs that could have become probands during the recruitment
period. In paper V we incorporate the relevant parts of the Finnish population to the full
likelihood function.
2.6 Genetic association
If a genotype occurs in study population more commonly among affected subjects than
among healthy subjects, this is called a genetic association. This association could be
noncausal because the marker could be in linkage disequilibrium with the truly causal gene.
As in epidemiology, association between genetic marker and a phenotype might exist because
1) the polymorphism has truly causal role (direct association) 2) polymorphism has no causal
role but is associated with nearby causal variant (indirect association) and 3) there is
population stratification/admixture (confounded association) (32). Observations of genetic
association can be confounded by population stratification, where unequal proportions of
alleles in latent subgroups can lead to spurious associations.  To avoid this it is possible to
collect data from well mixed population, to match according to geographical or ethnic origin,
to seek markers for subpopulation structure (33) or to search for genomic control to control
false positive rate (34). The characterization and mapping of genes using indirect method is
dependent on the association between causal variants and nearby markers.  This association of
loci is called a pairwise linkage disequilibrium (LD) in population genetics. LD can be
defined as joint occurrence of pairs of alleles in two linked loci more or less than expected by
random formation of haplotypes from alleles based on their frequencies. In genetic
association the same allele(s) are associated with the phenotype in a similar manner across the
whole study population. The amount of LD can be estimated by the square of standard
correlation coefficient between alleles at pair of loci and the allele at the disease locus or by
some other less common measure (35).
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Genetic association studies are therefore based on the genealogical history of the sampled
data.  The idea is that a disease mutation arises on a particular haplotype during the
genealogical history, and so individuals who inherit the mutation will also inherit the same
alleles at nearby marker loci.  At time of a disease mutation occurs, it is in complete linkage
disequilibrium with loci nearby. LD is diluted in each meiosis due to recombination between
the two loci,  recurrence of the same mutation and gene conversion.  It  has been argued that
association based methods will become more powerful than traditional linkage methods in
mapping genes with small effects on complex diseases because of population genealogy and
increasing number and density of marker information (microsatellite markers and SNP’s)
(36).  It has become clear that because the initial LD and the decay varies due to assumptions
of large population, mutation and selection, both within genome and between populations
therefore making it difficult to adopt general rules of studying complex diseases (32).
Traditional epidemiological study designs can be employed in studies relying on the genetic
association: cross-sectional, case-control, cohort and other more modern variations of these
classical study designs (nested case-control, case-cohort). More genetically oriented study
designs are based on observing information of the familial relationships: case-parent triads,
case-parent-grandparent sets, pedigrees and many variations of these including sibpairs and
twins studies. In this dissertation a cohort design is applied in papers III, IV and V. The study
design in paper I can be seen as case-parent triads but rather than testing a hypothesis of
recombination being 0.5 or LD being zero as in TDT-test we test the Mendel’s first law. The
study design of paper II can be viewed as an aggregated cohort of the Finnish population from
1965 to 1996.
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3. Type 1 diabetes
3.1 Pathogenesis of Type 1 diabetes
The detailed pathogenesis of T1D is unknown, but it is believed that joint action of
environmental and genetic factors is needed to either initialise or speed up the immune-
mediated selective destruction of the insulin-secreting  cells, in the pancreas. In T1D
patients, the pancreatic islets containing the  cells exhibit insulinitis, i.e. inflammation
characterized by the presence of T lymphocytes accompanied by macrophages, B
lymphocytes, without involvement of the glucagon-secreting -cells. T1D usually presents
itself with symptomatic hyperglycemia or ketoacodosis. The classic symptoms of
hyperglycemia are polyuria (frequent and abundant urination) followed by polydypsia (thirst
and high intake of liquids), and weight loss. Because high levels of glocose in the blood
produce osmotic diuresis (excessive loss of water, Na+ and K+ with urine), the symptoms can
progress to dehydration, which might include blurred vision, fatigue, and nausea.  If the loss
is massive, for example if precipitated by withdrawal of insulin or infection, the modulating
effect of insulin in hepatic activity is suppressed and hepatic ketone body synthesis and
release is increased and ketoacidosis might develop. Accumulation of ketons produces first
ketonuria (increased excretion of ketons in urine), and can progress to ketoacidosis, and if not
quickly corrected, to coma and death.
T1D accounts for approximately 10% of all diabetes and it has been a lethal disease until the
late 1920’s, when the insulin treatment was discovered. During the last decades several other
forms of diabetes in children and young adults have been discovered (MODY – mature onset
diabetes of the young (37); LADA - latent autoimmune diabetes of adulthood (38), and other
less frequent forms), which earlier might have confounded the T1D phenotype. Although T1D
commonly occurs in children, with peaks of incidence around the puberty or pre-puberty (39),
it can also develop in adults. Non-genetic factors potentially associated with T1D include
gender (40), birth order (41), diet (42), breast feeding (42,43), infections (44) and composition
of the drinking water (45).
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3.2  Epidemiology of T1D
The incidence of T1D shows variation according to many factors including: gender, age and
geographical areas. A significant spatial variation worldwide has been observed from 0.2 to
40/100,000 (46). Several epidemiological studies have shown that Finland has the highest
incidence of T1D in the world: during the 1990’s there were approximately 40/100,000 new
cases per year in children below 15 years of age (47), whereas the lowest incidence has been
observed in East Asia. Geographical differences in the incidence of T1D have been detected
within Finland as well.
The average increase in the incidence of T1D between 1965 and 1996 has been estimated to
be 0.67/100,000 per year (47). Findings concerning the age at onset distribution with respect
to calendar time are conflicting. While a study of the Finnish population indicated that age at
onset has become younger (48), a later study which accounted for the registry-based
ascertainment of the T1D cases, showed that the observed shift at the age at onset of T1D
could be explained by random variation (49).
3.2.1 Genetic epidemiology of T1D
Although T1D can be best identified as a chronic T-cell mediated autoimmune disease
attacking insulin-producing pancreatic cells, genetic susceptibility plays an important role on
its onset and development. As we have also seen above, the association of specific HLA
alleles and haplotypes with T1D is very strong, this genetic locus is estimated to account for
<50% of genetic contributions to disease susceptibility (50, 51). Diabetogenic alleles are not
fully penetrant, implying that not every individual who inherits the gene develops the disease.
Family studies have also shown the importance of genetic factors in determing T1D risk.
Sibling cumulative risk of affected subjects is approximately 6% while population risk is
0.5%, varying between populations. Further evidence for genetic factors comes from the large
population-based twin studies (52) and recent large population-based twin studies indicate a
clear genetic component in the risk of T1D (53). HLA region has constantly shown linkage as
well as association in all of the genome-wide linkage or candidate gene/genome-wide
association studies. IDDM2 (region containing INS gene, chromosome 11) and IDDM12
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(region containing CTL4 gene, chromosome 2) has been detected in multiple association
studies. Other loci IDDM3-IDDM18 in different chromosomes have been identified but
further replications are needed to avoid false-positive findings. It has been postulated that
multiple genes in various chromosomes could contribute to the risk of T1D with unknown
combined effects (54). At the moment there are 32 locations linked/associated with T1D (see
Figure 4), but HLA seems to confer the highest risk of all of the detected locations.
Figure : Locations in human genome linked/associated with Type 1 diabetes
And number of locations per chromosome
http://www.ncbi.nlm.nih.gov/mapview/
HLA region
Figure 4. Locations in human genome linked/associated with T1D and the number of
locations per chromosome.
One of the first genetic associations with human diseases was with HLA and T1D (55) and
the association was later pinpointed to the HLA-DR3 and DR4 containing chromosomes.
Interestingly HLA-DR3/DR4 heterozygotes were observed to confer higher risk of T1D than
DR3/DR3 or DR4/DR4 homozygotes. Further locating the gene have been complicated by the
strong long-range LD.  Very recent genome-wide scans have provided strong evidence of
IDDM1 (HLA region) (56) and this is consistent across different populations and studies.
3.3. Dime and DERI Studies
26
3.3.1 The DiMe Study and nationwide registry of T1D
The Childhood Diabetes in Finland (DiMe) study was a large population-based genetic-
epidemiologic family study of T1D (57). Nationwide, all T1D cases under the age of 15 in
Finland diagnosed during the calendar period from September 1987 to April 1989 were
identified. The cut-off age was chosen purely for practical reasons. Newly diagnosed children
under the age of 15 years with T1D were hospitalized in the pediatric wards in Finland and
therefore were easier to recruit than older subjects with T1D. T1D status was checked against
the data of the National Drug Registry. Of the 801 cases in the study 800 had also been
registered in the Drug Registry and one person died soon after the diagnosis. The participation
rate in the study was approximately 95%. Parents and siblings of the 801 probands were also
asked to participate. Extensive questionnaires were filled in and blood samples were taken
from participants. Probands, their parents and siblings were HLA genotyped at A, B, C and
DR loci using conventional serology (57,58). The ethical committees of the National Public
Health Institute and local hospitals approved the study protocol. Details of study procedures,
especially data collection, are described elsewhere (57). A polymorphism information
contents (PIC) was used to choose loci to the statistical analysis (11). Its value describes the
polymorphism within a sample and it is a function of the number of detectable alleles and
their frequency. Statistical analyses of the DiMe data were restricted to the HLA-A, HLA-B
and HLA-DR loci, which had the highest polymorphic information content (0.74, 0.89 and
0.73 respectively).
3.3.2 The Diabetes Epidemiology Research International Study (DERI)
The original cohort consisted of subjects with T1D diagnosed before the age of 18 years
between 1965 and 1979 (n = 5,126), who were included in the nationwide register of Finnish
T1D patients and comprised the Finnish contribution to the Diabetes Epidemiology Research
International (DERI) study (59,60). This register was initially based on the Social Insurance
Institution’s Drug Reimbursement Register, which lists patients approved to receive free-of-
charge medication for certain diseases, including diabetes. Their siblings (n=10,168) were
identified through the national population register of Finland. The diabetes status of the
siblings was ascertained through several sources: from the nationwide Hospital Discharge
Register for the years 1970–1998, fromthe nationwide Finnish Diabetes Register for children
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and young adults for the years 1965–1998, and from the Central Drug Register through
searching the records using the personal identification number assigned to all residents of
Finland. Because of these multiple data sources, the case ascertainment was virtually
complete. By the end of the year 1998, a total of 537 families that included 616 siblings with
T1D were identified among the original DERI cases (61). Because of missing information on
the time at onset of DN, nine families were excluded from the dataset used in the statistical
analysis. Therefore we had in the analysis 528 families, with total of 1134 T1D patients and
by the end of follow-up 321 DN cases were observed.
In order to identify patients with DN, copies of original medical records, death certificates,
and autopsy data for the probands and siblings were systematically reviewed by one of the
co-authors (V.H.). Overt nephropathy was defined when a patient repeatedly had either a
urinary albumin excretion rate of >200 μg/min or >300 mg/24 h, a 24-h urinary protein
excretion rate of >0.5 g, or a positive urinalysis for protein using a reagent strip.
Microalbuminuria was defined as a urinary albumin excretion rate of 20–200 μg/min or 30–
300 mg/24 h. Albumin elevations because of pregnancy, urinary tract infections, or other renal
diseases alone were not considered as diagnostic for DN. The urinary albumin excretion rate
had decreased in some patients because of the initiation of antihypertensive medication; in
such cases, the classification of DN was based on findings before the initiation of drug
treatment. Microalbuminuric patients were grouped together with normoalbuminuric subjects
in all analyses.
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4. Aims
The aim of this investigation is to develop novel statistical tools for genetic-epidemiological
studies and to assess the associations of T1D with genetic factors, especially HLA. To achieve
this aim following aspects are considered:
 Construction of  conditional likelihood of variable age-at-onset phenotype in population-
based ascertainment to assess Mendelian transmission of HLA-A, HLA-B and HLA-DR
loci.
 Derivation of the Poisson likelihood for the incidence trend with possible genetic
influence in order to consider whether non-Mendelian transmission of disease alleles lead
to increase in T1D observed in Finland.
 Modelling of the genetic association of variable age at onset disease with long-term
survivors in order to study the association between HLA and both susceptibility and age at
onset of T1D.
 Introduction of the familial segregation model with long-term survivors and to consider
the familial aggregation of susceptibility and age at onset of T1D nephropathy.
 Derivation  of  the  full  likelihood  function  for  variable  age  at  onset  phenotype  in
population-based registry data in order to make population-based analysis of the HLA-A,
HLA-B and HLA-DRB1 genotypes/haplotypes and the age at onset of T1D.
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5. Results
5.1. Statistical models and inference
Observing a family during the recruitment period does not depend only on the index child, but
rather on all siblings at risk of T1D during the recruitment period. This is accounted for in the
two approaches proposed for the ascertainment based on the variable age at onset in this
work:
1. In the conditional likelihood (papers I and III) approach the first born child who is
diagnosed in the ascertainment “window”, is considered a proband. Then the two sets
of siblings are eligible for the statistical analysis: a) those born before c0-w so that
they could not become probands and b) those born after the proband (younger than
proband).
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Figure 5. Lexis diagram illustrating construction of the conditional likelihood (siblings born
before 1972 and after the proband included in the analysis) of the population-based
ascertainment of all Finnish sibships which included an individual younger than 15 years who
was diagnosed with T1D during the recruitment period 1.1.1987-30.4.1989 (dotted area).
30
2. In the full likelihood (paper V) the ascertained family data is complemented by the
demographic information about the number of subjects at risk and external reference
sample of the genetic composition of non-ascertained population in order to formulate
statistically coherent likelihood function (cf  Figure 6).
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Figure 6. Lexis diagram of the population-based ascertainment of all Finnish sibships, that
included an individual younger than 15 years who was diagnosed with T1D during the
recruitment period 1.1.1987 - 30.4.1989. The start and end points of the recruitment
window are denoted by c0 and c1, respectively. Further, w is the maximum age at which an
individual can be ascertained (w equals 14 years here). The time interval (c0-w, c1)
contains all individuals at risk, such that they could have become the probands during the
recruitment. The time point c2 denotes the end of the follow-up period for the recruited
siblings. The sizes of birth cohorts 19891972 N,...,N are marked in the figure.
In more detail, we consider the situation where the proband has to be diagnosed between
1.1.1987 and 30.4.1989 and has to be less than 15 years of age at the time of diagnosis. The
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ascertainment is illustrated by Figures 5 and 6, were a hypothetical family is draw in the Lexis
diagram, together with the number of people at  risk of T1D. Notice that all  families with at
least one diabetic child diagnosed with T1D during the recruitment period are observed and
all subjects in these families are included in the analysis based on the full likelihood.
5.1.1. Conditional likelihood
Following symbols were used in the construction of the conditional likelihood function: let Tij
be the calendar time of diagnosis of IDDM of the jth child in family i. We follow the
convention that if there is no such diagnosis Tij = . Let Yij =  1c,Tmin ij , and let 	ij = 1 if c0 

Yij < c1, c0 – w
 bij

 c1 and Yij – bij < w. Here Yij is  the onset time of IDDM of child j in family i if 	ij = 1 (in
which case this child is a proband). Let r index   the  alleles  of  a  locus  (the  total  number  of
different alleles being A), a random variable Zijp is created, which gets value r, r = 1,…,A,  if
child j in family i got allele r from parent p, and writing the genotype of a child j in  family
i  ijfijmij Z,ZZ  , where m and f stand for mother and father, respectively. Consider the
observed  HLA  genotype  of  the jth child in the ith family, where gijp is the allele inherited
from parent p (where m indicates mother and f father). Let " #21 pipiip G,GG   be  the
observed genotype at that locus of parent p of the ith sibship, where superscripts 1 and 2
indicate the two alleles, because grandparental origin is not known. Let Ki be the birth order
of the index child (proband), that is diagnosed within the recruitment window. With this
notation the observed data can be written
   iijpipiijpijij J,...,j,I,...,;b,f,mp;G,G,g,,Y 11121 	 .
First, we assume that i) the birth dates of offspring and the genotypes of  the parents are
known, ii) for the sibships in the general population, transmitted parental alleles and affection
statuses are conditionally mutually independent and iii) the sibships are independent.
Assumption (ii) implies that the conditional independence is
      G,G,J,...,=j;b|kj;,Y,Zkj;,Y,Z fimiiijijijijijijij 1	$
	 . Because the truth of the
ascertainment event {Ki=k} can always be deduced from  kj;,Y,Z ijijij 
	 it will also be
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true that       .G,G,J,...,j;b|Kj;,Y,ZKj;,Y,Z fimiiijiijijijiijijij 1	$
	 But this shows
that, given   fimiiij G,GandJ,...,j;b 1 , the genotypes Zij of all siblings younger than the
index child Ki are always sampled independently of the events that led to the ascertainment of
the family. In other words, given genotypes of all siblings younger than the index child are
always sampled independently of the events that led to the ascertainment of the family.
In summary, inclusion of the sibship in the data does not depend only on the proband but on
the other siblings who where at risk of T1D at the time period of recruitment as well. This is
in contrast to the classical framework presented earlier and leaving out the proband only is not
a good method of correction. Thus, there are three possible subsets of children in each
sibship: (1) children who were older than 15 years at the beginning of the recruitment period
(obviously, the same conditional independence applies to all older siblings, in case there were
any), (2) children who were eligible to become a proband and older than the index child, or
the index child himself/herself, and (3) children younger than the index child. Excluding set 2
from analysis allows one to make unbiased inference without need to model the probability of
the ascertainment event. A likelihood function for the transmission of HLA-A, HLA-B and
HLA-DR locus alleles is then constructed using sets 1 and 3 based on the multinomial
transmission probabilities. The details of the above formulation are given in the paper I and
the same principles were applied in the formulation of the likelihood function in paper III.
5.1.2 Full likelihood
Because the above conditional likelihood leads to substantial loss of data and reduction in
statistical power, a full likelihood was presented in paper V. The full likelihood is based on
the hazard model for the risk of T1D covering the not ascertained population of Finland.
Next, some notation and available data sets are presented in order to be later able to define the
full likelihood:
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1) In the ascertained registry families with T1D, let i = 1, …, I indexing all the ascertained
families, j = 1, …, J i indexing the individuals (siblings) in the ith family, and ij being
the indicator for right censoring of the follow-up (ij  = 1 if individual j in family i was
diagnosed with T1D in the recruitment window, and ij = 0 if right censored, cf. Figure
6). Let p=m , f  index the parents of the ith family. Further, for the siblings in the family
data, let  ijlfijlmijl G,GG   be the marker genotypes over the set of loci of interest, l =
1,..., NL. The alleles received from the mother (m) and the father (f) are indexed
accordingly, and an analogous indexing is later used for haplotypes as well. Parental
genotypes are denoted by Fijlp
M
ijlp G,G . Finally, let ij be the disease onset indicator for
individual j in family i during the fixed follow-up period (calendar time), and
correspondingly, let Xij represent the age at onset or the age at a censoring event. The
observed data of the ascertained sibships are thus collectively represented by the set
 m,fpl,J...,j,,...,i,G,G,G X iFijlpMijlpijlpijij  DRB1,B,A,HLA,17681; .
2)  In the HLA genotyped subjects of the Bone Marrow Donor registry, let
  1,198361; DRBB,A,l,...,r,GGG CrlfCrlmCrl    be the set of genotypes for the
unrelated individuals in the BMDR database, using a notation analogous to the familial
data. These reference individuals are known not to have acquired T1D before the age w.
The genotype and haplotype frequencies for this reference population are collectively
denoted by ),...,( 1
C
gn
C
g
C
g gqqq   and ),...,( 1
C
hn
C
h
C
h hqqq  , respectively.
3)  Demographic data is defined by the numbers of subjects born during the time interval
(c0-w, c1);  19891972,...,b;Nb  .
The first part of the risk model specifies the hazard of acquiring T1D for individual j in family
i as a function of age a. We use a discrete time hazard model and index age a = 0,...,14
corresponding age intervals "  "  " 15,14,2,1,1,0  . For the genotype effect model, the hazard is
assumed to be of form
" # .G,Gexp ijlfijlmaija 
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Here a is a baseline hazard in the population and [Gijlm,Gijlf] are the genotype effects
representing the molecular marker information at l = HLA-A, HLA-B, HLA-DRB1, each
locus being considered and analyzed separately.
An assumption of the conditional independence of individual disease onset times given the
above hazard model parameters leads to the likelihood expression for all data:
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The next three factors in (2) are the contributions of the individuals (indexed here with k1, k2
and k3) in the background population, not belonging to the DiMe families and considered
individually, who were born between c0 – w and c1 and who therefore were at risk of being
diagnosed with T1D in the “ascertainment  window” (cf. Figure 6.). Technical details of the
calculations of the Bayesian modeling and calculations of the marginal survival function in
likelihood above are given in the paper IV.
5.1.3 A transmission distortion model for incidence of Type 1 diabetes
In the following, k is used to denote the genotype (  1,2,3k   for genotypes AA, Aa and aa,
respectively), b the birth cohort and , the transmission probability. Let )(tkq  denote the
genotype frequencies of genotype k in generation t, and let )()( and ta
t
A rr  denote the allele
frequency of 'A' and 'a' in generation t. The expected new genotype frequencies in generation
t+1 can be derived from the basic theorems of the population genetics. As the incidence of
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T1D in our data depends on the genetic susceptibility in children aged 14 years or under, the
genetic change should be calculated individually for every birth cohort. They are now treated
as genotype frequencies of the distinct annual birth cohorts, with the interval between two
consecutive generations chosen to be 25 years. In order to obtain the genotype frequencies for
annual birth cohorts between these generations, a linear approximation of the generation
specific genotypes was used, giving then    
   







 


25
1
1 t
k
t
k
kk
qq
bqbq  where qbk is the
genotype frequency in the birth cohort born in year b. The rate of change of the allele and
genotype frequencies depends on the deviation of , from the Mendelian expectation, 0.5. The
incidence is now a function of the birth cohort genotype frequencies and the penetrance
parameters.
The following notation was used: i= calendar year, j= age, b=i-j= year of birth (of a birth
cohort), Nb= size of the birth cohort obtained from the national population registry (constant),
dij= number of new cases of T1D in year i in the j-years-old, Nijk=number of genotype k
carriers in year i in age class j, qbk= q(i-j)k=the frequency of genotype k in the cohort born in
year b, ijk=penetrance for genotype k in year i at age j, q0=frequency of allele A in the year in
which insulin treatment was introduced (1930).
The observed data consist of  0,...,14,65,...,96  j , i, Nd ijij . In order to reduce the
number of parameters to be estimated, we suppose that ijk does not depend on i, i.e. ijk=jk
and further, that jk is constant in each of the age groups 0-4.99, 5-9.99, 10-14.99. We index
these three age groups by j=1,2,3.  Since T1D is a rare disease and we assume that the
numbers of new cases in each (i,j,k) cell are mutually independent, it is natural to have
  332211 where,Poisson~ jbjbjbijijij qqqd  .The log-likelihood is then
   " #-- 
j
ijijijij
i
!dloglogd , where  is a function of jk ( j,k=1,2,3), , and q0.
5.1.4 Long-term survival model for genetic association
36
To develop a model for the genetic association between susceptibility and age at onset of
disease and observed markers, some notation is first introduced. Let  ll A,...,a 1  index
alleles at locus l=1,…L, corresponding loci A,B,DR and let  
llAll ,...,... 1  be  a Al1
vector of regression coefficients for the allele effects at locus l on the susceptibility. Further,
let  Hh ,...,... 1  be a H1 vector of regression coefficients for the three locus haplotype
effects on the susceptibility, where H indexes all possible three locus haplotypes: 1,1,1, ….,
AA,AB,ADR. Regression coefficients for the age at onset are denoted respectively:
 
llAll ,..., 1  for the allele effects at locus l  and  Hh ,..., 1  haplotype effects. The
vectors of the observed marker genotypes at locus l  lijflijmlij g,gg   are  coded  as  a lAn
matrix .lZ ,  with  each  row
.
ijlZ being a vector of the genotype scores of locus l for the
susceptibility. Here, the upper index . indicates that this matrix codes for the susceptibility
effects.  Respectively, a matrix lZ  of the locus specific genotype scores that are used to
model the age at onset effects, where each row ijlZ  is a vector of the genotype scores for
subject j in family i. The two matrixes .lZ  and

lZ allow different dominance effects of the
loci l on the susceptibility and age at onset. Respectively Hn matrixes .hZ  and

hZ  are
defined using haplotype scores to model dominance of the haplotypes. When susceptibility is
modelled with multiplicative model, genotype scores are the number of alleles/haplotypes
carried by a subject j in family i (0  not  a  carrier,  1  one  copy  of  the  allele  and  2  is  subject
carries two copies of the allele of interest). Alternative dominance models are presented by
Thomas et al. and Cordell et al. (56, 57).
In papers III and V we choose to model the probability density of dichotomous partially latent
susceptibility Dij for subject j in family i using logit-function:
      ijijij
ijij
ijij gDp
gDp
gDp /


 









;|1
;|
ln;|logit  and let / be a (n1) vector of linear predictors
of subject j in family i. In paper III we model the genetic association of T1D susceptibility
with HLA marker data using logistic regression model for the allele effects:
ll
l
Z ../ .-0 , here the model parameters of interest are  l,...,, ... 10 .  In  the
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haplotype model the linear predictor for subject j in family i is hhZ ../
.
0 , where
 h,.. 0  and linear predictor for the joint allele and haplotype effects model is
hhll
l
ZZ .../ ..-0 , where  hle ,,...,,, ..... 10 .  Age  at  onset  is  modelled
with 2-parameter gamma distribution:  ,s,a;g|Yf ijijij where the shape parameter is in case
of allele effects model   -  
l
llZalog 0 , haplotype   hhZalog 

0  and joint model
  hh
l
ll ZZalog 
-0 . For the age at onset we used dominant model in all three
fitted models in paper III. Genotype/haplotype scores for the allele effects/haplotype were
assigned to the elements of the matrix ijlZ and

ijhZ according to dominant model, because
multiplicative assumption of allele/haplotype effects on the mean age at onset was considered
too restrictive. Details of the likelihood function for the ascertained sibships and construction
of the joint probability density of siblings family i are given in paper III, but in principle was
constructed using conditional likelihood described earlier in this work. The simulation study
in paper III showed that the existence of non-susceptible subjects in the population may lead
to biased estimates of genetic association, when the disease and age-at-onset parameters are
analysed separately.
5.1.5 Modelling familial aggregation and segregation in long-term survivors
In order to study clustering of nephropathy of T1D in Finnish families statistical models for
the aggregation and segregation were developed. The aim was to estimate the proportion of
subjects susceptible to diabetic nephropathy while accounting for unmeasured familial factors
(61). This was achieved by using latent variables to account for familial dependencies both in
susceptibility and age at onset.
5.1.5.1 Shared LTS random effects model
In order to introduce the LTS shared random effects model, some notation is first laid out. Let
 p,...,... 1  be a (1p) vector of regression coefficients for the effects of the covariates p-
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observed covariates  ijpijij z,...,zz 1  on the susceptibility  and  p,..., 1  corresponding
vector for covariates influencing the age at onset. The ia  and ib are the unobserved random
effects of family i that describe the variation between families (sibships), quantified by
variances 2.0  and
2
0 ,   for the susceptibility and age at onset that is not explained by other
covariates in the shared LTS model.  The probability density of the age at onset is modelled
with a 2-parameter Weibull density:        00 100   ijijijijijijij /Texp/T/,;Tf
, where 0 is the shape and ij is the scale parameter. In the shared random effects model we
simply assume
 ijpBernoulli~ijD ,   iij az' .. 0ijplogit
   iij bz  'exp,,Weibull~1D|T 0ijij0ijij 
The Weibull function was chosen on the basis of statistical simplicity in the long-term
survivor model. In the shared random effects model, the parameters of interest are
 02020 00. . ,,,, , where .0 is the risk of susceptibility in the base population and  the
parameters of the age at onset are: 0 is  the  "baseline"  age  at  onset  scale  parameter  of  the
Weibull distribution,  20 .0,N~ai is the random effect of the susceptibility,  20 0,N~bi
is the random effect of the scale parameter of the Weibull age at onset distribution and  is the
inverse of the shape parameter. Simulation study of sibships with long-term survivors showed
that all coverage rates of 95% credible intervals from the shared LTS model were at least at
the nominal level. As expected the model is sensitive to the choice of informative priors for
the variances of the random effects. However, with larger families the estimates had better
coverage even with informative priors.
5.1.5.2 ACE-LTS model for nuclear families
In the ACE-LTS variance component model (cf. Figure 7) we define variance components of
the additive genetic, common family environment and common sibling environment
separately for susceptibility  222 vcsvc ,, 000.  and age at onset  222 vcstvctat ,, 000 . We use the
reparametrization introduced by Burton et al. (62) in the generalized mixed linear model
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framework. The random effect bi in the model on previous page is replaced by independent
additive random latent variables iii HGF ,, , R
P
ij and RCij for susceptibility and iii HTGTFT ,, ,
RTPij and RTCij. These describe the effects of additive polygenic, common family
environment and shared sibling environment. Trait (susceptibility and age-at-onset) variation
can be factored to variance components by replacing bi for fathers with following:
ii GTFT  +RT
P
ij, for mothers ii GTFT  +RT
P
ij and for children ii HTFT  + RT
C
ij.
Corresponding random effects of ai for susceptibility are replaced with ii GF  +RT
P
ij,
ii GF  +RT
P
ij and ii HF  +RT
C
ij.
Figure 7. Directed acyclic graph of additive genetic variance component (random effects)
long-term survivor model for nuclear families. Here Dij is the binary susceptibility variable
and the pair  describes the failure and the age at onset for subject j in family i. The
222 and vcsvc, 000.  are the variance components of the additive genetic, common family
environment and common sibling environment separately for susceptibility and
222 and vcstvctat , 000 are the corresponding variance components for the age at onset.
The choice of priors and the formulation of the joint  posterior density is  given in paper IV,
together with Random-walk MCMC algorithm to obtain samples from the joint posterior of
ACE-LTS model.  In the simulation study we observed reasonable coverage rates for all
parameters with non-informative priors. However, the ACE-LTS model is even more
sensitive  than  the  shared  LTS model  to  the  choice  of  priors  of  variances  of  random effects
since informative priors clearly resulted in even poorer coverage rates.
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5.2 Results of the data analysis
5.2.1  Transmission of HLA-A, HLA-B and HLA-DRB1 alleles
To  analyze  transmission  of  alleles  at  the  HLA-A,  HLA-B  and  HLA-DRB1  loci  we  made
series of the goodness-of-fit tests: maternal alleles at the A locus (12=13.7, 13 df., p=0.40),
paternal  alleles  at  the  A  locus  (12=17.06, 12 df., p=0.15), maternal alleles at the B locus
(12=39.59, 35 df., p=0.27) and paternal alleles at the B locus (12=24.84, 31 df., p=0.78),
maternal at the DR locus (12=17.4, 27 df., p=0.92) and paternal at the DR locus (12=13.3, 17
df., p=0.72), where single allele transmissions are estimated simultaneously and there are less
parameters to be estimated than in the global test. Single allele transmission probabilities were
calculated to reveal individually the alleles inherited in a non-Mendelian fashion. Even
though some single allele transmission frequencies were statistically significantly different
from 50%, these findings cannot be considered conclusive as the significance levels have not
been corrected for multiple comparisons. Therefore, we conclude that the existence of strong
transmission distortion in the considered loci is excluded by our study.
5.2.2  Transmission distortion of susceptibility alleles and incidence of T1D in Finland
Two models were fitted using Poisson model described earlier: one with transmission
probability fixed at 0.5 (M0) and another where transmission probability was estimated from
the data (M1). According to the likelihood ratio test the model M2 resulted in a significantly
better fit (12=131.12, 1 df., p<0.001). The point estimate of transmission distortion , was 0.86
with estimated gene frequencies (0.06, 0.37, 0.57).  In Figure 8 the observed incidence of
T1D and expected incidence based on the models M1 and M2 are plotted.
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Figure 8. The observed incidence of T1D in Finland from 1965 to 1996 and expected
incidence under two models: (M0) no transmission distortion (transmission probability fixed
at 0.5) and (M1) allowing transmission distortion (transmission probability has been set to the
estimated value of 0.998).
The fitted model allows only non-Mendelian transmission of susceptibility gene alleles as an
explanation of the observed increase in the incidence of T1D. As shown by the Figures 1 a-b
in paper II, the alleles frequencies may increase in the course of few generations with
increasing transmission probability. It is obvious from these simple theoretical considerations
that,  given  the  current  knowledge  of  the  risk  alleles  of  T1D,  only  an  extreme  transmission
distortion of susceptibility alleles with high risk could explain the observed rapid increase in
T1D from 1965 to 1988 in Finland.
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5.2.3  HLA-A, HLA-B and HLA-DRB1 associations with susceptibility and age at onset of
T1D
To study the association of HLA-A, HLA-B and HLA-DR locus with susceptibility and age at
onset of T1D we fitted four models to the DiMe sibships data at A, B and DR locus: locus-
specific allele main effects (M0), joint allele main effects (M1), three locus haplotype effects
(M2) and three locus joint allele main and haplotype effects (M3). No statistically significant
susceptibility or age at onset effects were detected either at the A or at the B locus. At the DR
locus both DR3 (regression coefficient 1.17, p=0.012) and DR4 (regression coefficient 1.29,
p=0.005) were associated with susceptibility to T1D. These correspond to increased
susceptibility of 10.7% with DR3 heterozygote, and 12.5% with DR4 heterozygote with
respect to the overall mean. The mean age at onset of a DR3 carrier was 18.5 years (p=0.012).
The  only  significant  allele  main  effect  with  the  age  at  onset  of  T1D was  observed  for  DR6
(mean age at onset 12.1, p=0.010).
To assess independent allele effects and take into account the linkage disequilibrium between
A, B and DR loci, we performed the joint allele main effects analysis of A, B and DR loci
(M1), and the joint allele main and three locus haplotype effects analyses (M3). Only B62
was significantly associated with increased susceptibility to T1D, after adjusting for haplotype
effects (p=0.016). At the B locus, B8 carriers (p=0.0001) had older age at onset than all T1D
cases. At the DR locus, DR3 (p=0.001) and DR6 (p=0.0233) showed significant effects with
the earlier age at onset of T1D compared with the overall mean (after adjusting for haplotype
effects).
When three locus haplotypes main effects were investigated we found three haplotypes
associated with higher than average susceptibility (A1B8DR3; A2B62DR4; A2B8DR3).
However, all these associations disappeared in the joint allele main effects and haplotype
analysis (M3). Older than average age at onset was observed in A3B18DR4, and it remained
significant after adjusting for allele main effects (p=4.0e-5). Due to the ascertainment
correction and subsequent loss of data we have very low power to detect any significant
association especially with such complex model with many parameters to be estimated.
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5.2.4 Familial aggregation of susceptibility and age at onset of T1D nephropathy
In paper V, we analyzed the susceptibility and age at onset of DN by simulating the joint
posterior distribution of the model parameters of three different models: (i) the measured
covariates only (M0), (ii) latent random effects only (M1) and (iii) both measured covariates
and  variance  component  model  (M2).  Gender  was  assumed  to  influence  both  the
susceptibility and age at onset. The age at onset of T1D was assumed to influence the time to
the  onset  of  DN,  because  if  the  age  at  onset  of  T1D  was  very  young  this  might  lead  to  an
earlier development of DN than in T1D patients with a later age at onset.
The estimated proportion of male T1D patients susceptible to DN was 53.5% (46.5%; 61.1%,
95% credible interval) and among female T1D patients 37.5 % (31.2%; 45.0%) when no
familial  clustering  was  accounted  for,  based  on  the  model  M0.  However,  the  difference
increased when shared sibship effects were accounted for in model M2: males 58.9% (45.7%;
70.8%) and females 33.8% (23.1%; 46.5%). A large familial variation in the susceptibility of
DN was reflected by the posterior mean of the variance 2.96 (0.72; 7.00). The posterior mean
of  the  time to  the  onset  of  DN from the  diagnosis  of  T1D was  19.9  years  (17.4;  23.0).  No
significant difference between males and females was observed in the time to DN from the
diagnosis of T1D, after taking into account the familial  effects.  The variance of time to DN
related to familial clustering was small 0.08 (0.03; 0.17) and remained virtually unchanged
when sex and age at onset of T1D were adjusted for.
5.2.5 HLA A, B and DRB1 associations with age at onset of T1D
The results concerning full likelihood based analysis of the association between T1D and
HLA-A, HLA-B and HLA-DRB1 genotypes are presented using predictive probabilities of
T1D free survivals. The heterozygous genotype DR3/DR4 at the DRB1 locus was associated
with the lowest predictive probability of the T1D free survival to age 15, the estimate being
0.936 (0.926; 0.948, 95% credible interval), compared to the average population T1D free
survival probability 0.995.  The effect of DR4 homozygote was also strong with associated
probability 0.962 (0.954; 0.969) of T1D free survival. Carriers of DR 3/3 genotype, with T1D
predictive probability 0.994 (0.990; 0.998), were close to the population average probability
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of T1D free survival. Carriers of DR1/DR2, a common genotype in the reference population
and of DR2/DR6, had virtually no risk of T1DM before age 15, with predictive probability for
T1D free survival being very close to 1 (0.999; 1.000). At the A locus A1/9 and A2/3 carriers
had the lowest predictive probability of the T1D free survival to age 15, 0.983 (0.976; 0.988)
and 0.993 (0.992; 0.995) respectively. At the B-locus carriers of B8/22 and 8/15 genotypes
had 0.963 (0.944; 0.977) and 0.980 (0.974; 0.984) predictive probability of the T1D free
survival to age 15, while carriers of B7/35 and B5/B7 had virtually no risk of T1D before the
age 15. To illustrate the age dependency of the HLA-DRB1 genotypes, predictive disease free
survivals for some HLA-DRB1 high risk genotypes are plotted in Figure 9.
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Figure 9. Predicted disease-free survival of T1D for some high risk HLA-DRB1 genotypes.
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6. Discussion
It is both time and financial resources consuming effort to collect registry data which serves
as data source for many future studies. Therefore, it would be atmost importance to analyze
such data in a statistically coherent way. In this work, I present new statistical methods for the
analysis of population-based familial data ascertained through an incident case(s) in genetic
association studies of complex human diseases and for the genetic analysis of variable age at
onset diseases with non-susceptible subjects. New knowledge is provided concerning the
genetic effects of HLA to the T1D risk and familial aggregation of diabetic nephropathy.
The analysis of disease registry data in this thesis is based either on modelling of the disease
risk in the entire population (paper IV) or restricting statistical analysis to those individuals
that did not contribute to the ascertainment event (paper I). We have replicated the well
known association between HLA-DR3,4 and T1D  in our population-based analyses of
population based registry of T1D. This is in contrast to unsuccessful replications of
associations in many other complex diseases (67). Further, we do not find any support of non-
Mendelian transmission of HLA-A, HLA-B and HLA-DRB1 alleles, when accounting for the
ascertainment. We failed to reject the hypothesis of Mendelian transmission of alleles at the
HLA-A,  HLA-B  and  HLA-DRB1  loci  in  paper  I,  despite  the  results  of  earlier  studies
suggesting non-Mendelian transmission (68,69). Partly these earlier findings can be explained
by lack of proper ascertainment correction and a proper analysis would use large population-
based random sample. As we observed, non-Mendelian transmission of T1D susceptibility
alleles does not look like the explanation of the observed increase of T1D incidence in
Finland nor have there been proposed any other genetic mechanism that would explain this
phenomenon (65).  Although we were not able to make very strong conclusion concerning the
association  of  HLA-A,  HLA-B  and  HLA-DR  serological  genotypes  with  susceptibility  and
age at onset, recent findings with more accurate HLA-DRB1 data seem to support such an
association (66).
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Finding complex disease genes with modest effects has turned out to be much more difficult
than expelling genes for monogenic diseases. With increasing ability to genotype large
materials and combining various already existing data sources (disease registries, population
based-biobanks and demographic data) a substantial gain can be obtained in the search for
genes of complex diseases like T1D (63). One possibility to increase statistical power is to
increase sample size by incorporating the whole population in the statistical analysis. Another
advantage of our analysis using full likelihood is that population average incidence can be
used as “natural” reference level when genotypes are assessed to confer increased or reduced
risk. Population stratification has been named as one of the reasons for the failure to find or
replicate genetic associations with diseases (67) and many approaches have been proposed
(33,70) and it should be further studied with respect to ascertainment of family data.
A complex variable age at onset phenotype with non-susceptible subjects is modelled and
estimated both with observed genetic marker data (paper III) and without (paper V). Long-
term survival segregation model revealed a substantial familial contribution to the
susceptibility of T1D related nephropathy and suggestive findings of marker alleles at the
HLA  region  to  be  associated  with  both  to  susceptibility  and  age  at  onset  of  T1D  were
detected. In search for complex disease genes one alternative is to explore sophisticated
statistical models for complex phenotypes, like long-term survivor model. This may be
motivated by the emerging new subtypes of T1D during past decades and more is to be
expected with the rapid development of our ability to assess metabolic pathways of diseases.
These more refined phenotypes may be more accurate in search for disease-causing genes,
requiring more complex statistical models. A long-term survivor model, in which age at onset
distribution can be used to make inference concerning susceptibility, has been recently
applied to studies of genetic association (23,24). However, in neither of these studies the
random variable describing susceptibility status was sampled as part of the model like the
Bayesian model presented in paper V. Neither was the probability of susceptibility further
modelled as a function of latent or observed variables. As shown in paper V, the hierarchical
LTS model is sensitive to the choice of priors (64), especially when estimating variance
components of the susceptibility and this should be further explored. Although segregation
analysis has been applied less often since the introduction of modern genetic technology, it
remains a valuable tool when combined with modern statistical models for genetic
epidemiology as describing influence of genetic and environmental factors at the population
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level and possibly evaluating the importance of residual variation after some functional genes
has been identified.
With the development of large disease or population-based biobanks (63) and increasing
accuracy of genetic information (HapMap project)  computer intensive statistical methods,
such as Bayesian methods applied in this thesis, can be utilized to analyze such a considerable
amount of data.  As this thesis provides new ways to take into account the collection of
registry data and complex variable age at onset disease, it is hoped that future registry-based
studies will benefit from the statistical methods proposed here.
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